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(b) Pre-treatment of BMDCs with BRD6989 minimally elevates IL-1β production induced by stimulation with R848 or Zymosan A (each point corresponds to mean ± S.D.; n = 3 biological replicates from 1 independent experiment). (c) Pre-treatment of BMDMs with BRD6989 or dCA up-regulates IL-10 production by R848-or Zymosan A-stimulated BMDMs (each bar corresponds to mean ± S.D.; n = 3 biological replicates for 1 independent experiment). ***, P < 0.001 using one-way ANOVA with Dunnett's post-test. (d) Effect of BRD6989 on IL-10 production in human DCs stimulated with R848 (each point corresponds to mean ± S.D.; n=3 biological replicates from 1 independent experiment using cells derived from 1 donor). (e) Chemical structure of the pan-SIK inhibitor HG-9-91-01 (4). (f) Effect of pre-treating BMDCs with HG-9-91-01 (0.5 µM) or BRD6989 (5 µM) on Il10 mRNA levels following stimulation with R848 (each point corresponds to mean ± S.D.; n = 4 biological replicates from 1 independent experiment; *, P < 0.05; ***, P < 0.001 using unpaired, two-tailed Student's t test). Data from all panels is representative of at least 2 independent experiments. (each point corresponds to mean ± S.D.; n=3 biological replicates from 1 independent experiment using cells derived from 1 donor; Data is representative to 2 independent experiments). (b) Chemical structure of the CDK7 inhibitor THZ-1 (7). (c) Effect of CDK7 inhibitor THZ1 on viability and IL-10 production of R848-stimulated BMDCs (each point corresponds to mean ± S.D.; n = 4 biological replicates from 1 independent experiment). (d) IL-10 levels were quantified in tissue culture media generated during differentiation of naïve, splenic CD4 + T cells into T reg 's in the presence of dCA (0.1 µM) or BRD6989 (5 µM) (each point correspond to mean ± S.D.; n = 3 biological replicates from 1 independent experiment; *, P < 0.05; n.s., not significant; one-way ANOVA with Dunnett's post-test). Data from all panels is representative of at least 2 independent experiments. Supplementary Figure 7 . Upregulation of IL-10 by CDK8 inhibitors requires an intact Cyclin C/CDK8 complex. (a) Genotyping PCR of genomic DNA and immunoblotting of whole cell lysates confirms recombination of the Ccnc locus and reduction of Cyclin C levels, respectively, in BMDCs derived from Ccnc Δ/Δ mice (full gel images are presented in Supplementary Fig. 11 ). (b) Reduction of cyclin C levels in BMDCs does not alter basal levels of IL-10 production in response to R848 (each bar represents mean ± S.D.; n = 3 independent biological replicates from 3 pairs of Ccnc (2 µg/mL) for the indicated time points. (Immunoblotting data is representative to 2 independent experiments; full gel images are presented in Supplementary Fig. 11) . CpG, synthetic CpG-containing oligonucleotide; FLA, flagellin; LPS, lipopolysaccharide; MDP, muramyldipeptide; Pam3cys, synthetic triacylated lipoprotein; Poly(I:C), polyinosinic-polycytidylic acid ; SeV, Sendai virus; TDB, trehalose-6,6-dibehenate. Supplementary Fig. 11 ). (c) Chemical structure of the c-Fos/AP1 inhibitor T-5224 (8). (c) Co-incubation of BMDCs with T-5224 (100 µM) and the indicated concentration of the pan-SIK inhibitor HG-9-91-01 does not affect up-regulation of IL-10 or suppression of IL-6 in Zymosan A-stimulated BMDCs (each data point corresponds to mean ± S.D.; n = 3 biological replicates for 1 independent experiment). (d) Co-incubation of BMDCs with T-5224 (100 µM) and the indicated concentration of the dCA does not affect production of IL-6 or TNFα in R848-
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